- Home
- DXR
as of 12-12-2025 3:47pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 61.5M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 4.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | 3.46 |
| 52 Week Low/High: | $6.55 - $14.15 | Next Earning Date: | 01-01-0001 |
| Revenue: | $66,306 | Revenue Growth: | -57.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered DXR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Daxor Corporation (DXR)
Chief Financial Officer
Avg Cost/Share
$0.00
Shares
3,000
Total Value
$0.00
Owned After
20,050
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$0.00
Shares
18,000
Total Value
$0.00
Owned After
53,908
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$0.00
Shares
2,344
Total Value
$0.00
Owned After
17,616
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Michel Robert J | DXR | Chief Financial Officer | Dec 9, 2025 | Buy | $0.00 | 3,000 | $0.00 | 20,050 | |
| Feldschuh Jonathan Adam | DXR | Chief Scientific Officer | Dec 9, 2025 | Buy | $0.00 | 18,000 | $0.00 | 53,908 | |
| Jefferies John | DXR | Chief Medical Officer | Nov 12, 2025 | Buy | $0.00 | 2,344 | $0.00 | 17,616 |
Compare DXR vs Leading Stocks
See how DXR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.